The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Genentech Inc  (DNA) Trade Now »     Rate DNA  -  Discuss DNA  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
82.5%
Top:
63.5%
Rate DNA:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

DNA: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Upcoming FDA Advisory Panel Meetings Graphic_rating_buy DNA
Mikerun
73%

A trio of diabetes drug candidates are affected by a tougher stance at the FDA for this class of drugs, which is focused on cardiovascular risks such as heart attack and stroke. Two of the drugs will be reviewed at early April FDA advisory panel meeting while a third will likely require additional clinical trials.

http://www.biomedreports.com/fda-calendar.html

<> In December the FDA issued a new guidance document that recommended more stringent clinical trials for diabetes drugs to better assess heart attack and stroke risks. In a change that was effective immediately,...
By  Mike Havrilla   (+1.04%  risk: conservative)  03/09/09 Comment


FDA Decision Calendar: Pain Drug Delays Likely Graphic_rating_buy DNA
Mikerun
73%
FDA Decision Calendar: Pain Drug Delays Likely
By Mike Havrilla on 2/9/09
ETF Innovators
 
The tables at my website link below include an updated calendar of 86 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions or new submissions for regulatory approval. Click here for a link to my previous calendars.
 
 
New FDA Decision Calendar Entries:
 
<> 1.) Biogen Idec (BIIB) and Genentech (DNA) have a PDUFA...
By  Mike Havrilla   (+1.04%  risk: conservative)  02/10/09 Comment


Calendar of 163 FDA Decisions and Clinical Trials Graphic_rating_buy DNA
Mikerun
73%
The tables at my web link below include an updated calendar of 80 expected FDA new product decisions and 83 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and the below is a summary of new entries and updates on the calendars.
 
 
<> 1.) Genentech (DNA) expects to report results in mid-April in its Avastin colon cancer adjuvant trial, in addition to pending FDA decisions to expand product labels for Avastin in relaps...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/21/09 1 comment


Buyout Binge Begins for Bio-Pharma, Diagnostics Graphic_rating_buy DNA
Mikerun
73%

Buyout Binge Begins for Bio-Pharma, Diagnostics

<>
<>
<> With news late Friday that Roche (RHHBY) is prepared to up its bid for complete control of Genentech (DNA) to $95 from a previous offer of $89 per share and a $41M ($1.50 per share) all-stock takeover offer by Sequenom (SQNM) for EXACT Sciences (EXAS); 2009 is off to a strong start for M&A activity in the bio-pharma and diagnostic space.

Larger and well funded bio-pharma and diagnostic companies are opportunistically looking to expand their product offerings, pipeline prospects, patent portfolios, ...
By  Mike Havrilla   (+1.04%  risk: conservative)  01/10/09 Comment


A More Focused Highly Defensive Index Graphic_rating_buy DNA
Mikerun
73%

A More Focused Highly Defensive Index

<>
The accompanying table [click to enlarge] includes an updated version of the ETF Innovators [ETFI] ETFI Highly Defensive PerformIdex of 36 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. This update includes a 10% reduction in the number of companies with an equal distribution of 12 each from consumer staples and healthcare, with the remaining 12 companies chosen from a variety of defensive industry groups.

(A) Mass Merch...
By  Mike Havrilla   (+1.04%  risk: conservative)  12/03/08 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.25% 381
2 Gerald Greene 18.14 +72.34% 210
3 stockmarketfunding.com 17.66 +25.65% 55
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +76.91% 39


POPULAR STOCKS
Symbol Company Name Sentiment
SIRI Sirius Satellite Radio Inc
WFC Wells Fargo & Company
MSFT Microsoft Corp
GOOG Google Inc
C Citigroup Inc
MCD McDonald's Corp.

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on DNA

Visit streetinsider.com


Discussion Wall + Add  
Brandon Jackson   (+22.89%  risk: moderate)
Trader who needs HELP!! - Im looking for a Stock Pick Website. What are the most important things for me to look for? What makes a good Stock Pick site? What sort of content sho
+   10 replies

128_by_128_cp
Contrarian Profits   (-2.09%  risk: conservative)
3 Clean Energy Stocks For An Obama Presidency - How will the stock markets respond to a new US president? Martin Delholm says the impact will be less than some people expect. But some sectors will be...
+   0 replies


More Resources

Graphic_arrow1 About Genentech Inc - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch